Literature DB >> 19642913

T-oligo induces apoptosis in advanced prostate cancer cells.

Munirathinam Gnanasekar1, Sivasakthivel Thirugnanam, Guoxing Zheng, Aoshuang Chen, Kalyanasundaram Ramaswamy.   

Abstract

Prostate cancer is the most frequently diagnosed malignancy in men. As cancer progresses from an androgen-sensitive stage to hormone-refractory stage, it turns resistant to androgen ablation therapy. At this stage, effective newer therapies that induce apoptosis are needed for treatment of prostate cancer. DNA oligonucleotides homologous to the telomere 3' overhang (T-oligo) induce apoptosis in several human cancer cells. In the present study, we studied the effect of T-oligo on prostate cancer cells. Our studies showed that androgen-independent DU-145 cells are sensitive to T-oligo in terms of inhibition of proliferation. Moreover, T-oligo induced DU-145 cells to undergo apoptosis. Therefore, our results are encouraging for further investigation in the potential application of T-oligo as a novel therapeutic approach for prostate cancer, especially the androgen-independent.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19642913     DOI: 10.1089/oli.2009.0179

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  12 in total

1.  Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.

Authors:  Neelu Puri; Ryan T Pitman; Richard E Mulnix; Terrianne Erickson; Audra N Iness; Connie Vitali; Yutong Zhao; Ravi Salgia
Journal:  Cancer Lett       Date:  2013-09-14       Impact factor: 8.679

2.  Star-shaped tetraspermine enhances cellular uptake and cytotoxicity of T-oligo in prostate cancer cells.

Authors:  Vidula Kolhatkar; Hiren Khambati; Asawari Lote; Peter Shanine; Thomas Insley; Soumyo Sen; Gnanasekar Munirathinam; Petr Král; Rohit Kolhatkar
Journal:  Pharm Res       Date:  2014-08-05       Impact factor: 4.200

3.  Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells.

Authors:  Andrew M Rankin; Lora Forman; Sibaji Sarkar; Douglas V Faller
Journal:  Nucleic Acid Ther       Date:  2013-08-24       Impact factor: 5.486

4.  Telomere Fragment Induced Amnion Cell Senescence: A Contributor to Parturition?

Authors:  Jossimara Polettini; Faranak Behnia; Brandie D Taylor; George R Saade; Robert N Taylor; Ramkumar Menon
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

5.  Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma.

Authors:  Ryan T Pitman; Luke Wojdyla; Neelu Puri
Journal:  Oncotarget       Date:  2013-05

6.  Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy.

Authors:  Srijayaprakash B Uppada; Terrianne Erickson; Luke Wojdyla; David N Moravec; Ziyuan Song; Jianjun Cheng; Neelu Puri
Journal:  Int J Nanomedicine       Date:  2013-12-17

Review 7.  Treating Cancer by Targeting Telomeres and Telomerase.

Authors:  Marko Ivancich; Zachary Schrank; Luke Wojdyla; Brandon Leviskas; Adijan Kuckovic; Ankita Sanjali; Neelu Puri
Journal:  Antioxidants (Basel)       Date:  2017-02-19

Review 8.  Effect of therapies-mediated modulation of telomere and/or telomerase on cancer cells radiosensitivity.

Authors:  Ganiou Assani; Yudi Xiong; Fuxiang Zhou; Yunfeng Zhou
Journal:  Oncotarget       Date:  2018-10-09

9.  Beyond Telomerase: Telomere Instability as a Novel Target for Cancer Therapy.

Authors:  Maria Fadri-Moskwik; Qing Zhou; Weihang Chai
Journal:  J Mol Genet Med       Date:  2013-12-09

Review 10.  Structural Features of Nucleoprotein CST/Shelterin Complex Involved in the Telomere Maintenance and Its Association with Disease Mutations.

Authors:  Mohd Amir; Parvez Khan; Aarfa Queen; Ravins Dohare; Mohamed F Alajmi; Afzal Hussain; Asimul Islam; Faizan Ahmad; Imtaiyaz Hassan
Journal:  Cells       Date:  2020-02-04       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.